JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.R000003200 on May 4, 2000

J. Biol. Chem., Vol. 275, Issue 29, 21785-21788, July 21, 2000
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/29/21785    most recent
R000003200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plow, E. F.
Right arrow Articles by Smith, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plow, E. F.
Right arrow Articles by Smith, J. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

MINIREVIEW
Ligand Binding to Integrins*

Edward F. PlowDagger §, Thomas A. HaasDagger , Li Zhang, Joseph Loftus||, and Jeffrey W. Smith**

From the Dagger  Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio 44195,  Vascular Biology Department, American Red Cross Holland Laboratory, Rockville, Maryland 20855, || Del E. Webb Foundation Research Laboratory, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, and ** Cancer Research Center, The Burnham Institute, La Jolla, California 92037

    INTRODUCTION
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

The "integrin" terminology was applied in a 1987 review article (1) to describe a family of structurally, immunochemically, and functionally related cell-surface heterodimeric receptors, which integrated the extracellular matrix with the intracellular cytoskeleton to mediate cell migration and adhesion. The three original beta  subunits (beta 1, beta 2, and beta 3) identified have now expanded to eight, and the number of alpha  subunits stands at 17. These subunits interact noncovalently in a restricted manner to form more than 20 family members. The diversity of integrins is expanded further by alternative splicing, post-translational modifications, and interactions with other cell-surface and intracellular molecules (2-4). The number of integrins and the remarkable breadth of their cellular distribution support the statement that the phenotype of virtually every cell is uniquely influenced by its display of integrins. Over the past 13 years, more than 14,000 scientific articles have dealt with various aspects of integrin biology and almost 1,000 have appeared in the Journal of Biological Chemistry. This article examines a central aspect of integrin biology: ligand recognition and the structural basis for this function.

    Ligand Repertoire and Recognition
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

Repertoire Considerations-- A hallmark of the integrins is the ability of individual family members to recognize multiple ligands. Indeed, the extent of the integrin family pales in comparison with the number of their ligands. Table I summarizes the major extracellular ligands of integrins; the listing is undoubtedly incomplete. The list includes a large number of extracellular matrix proteins (bone matrix proteins, collagens, fibronectins, fibrinogen, laminins, thrombospondins, vitronectin, and von Willebrand factor), reflecting the primary function of integrins in cell adhesion to extracellular matrices. Many "counter-receptors" are ligands, reflecting the role of integrins in mediating cell-cell interactions. Included are numerous microorganisms, which utilize integrins to gain entry into cells. There are direct and multiple linkages between integrins and host defense systems, created by their recognition of hemostatic and complement factors. The preference of any given integrin among its ligands is determined by relative affinity, availability within a specific microenvironment, and the conformational state of the ligand, which controls exposure of its integrin recognition sequence.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Integrin extracellular ligands

Integrin Recognition Sequences-- A primary goal of many structure-function analyses in the integrin field has been the reduction of macromolecular ligands to minimal recognition sequences. This endeavor has been highly successful, and many bioactive amino acid sequences have been teased out of large extracellular matrix proteins (5). The prototypic example is the RGD sequence. RGD was originally identified as the sequence in fibronectin that engages the fibronectin receptor, integrin alpha 5beta 1, but now is known to serve as a recognition motif in multiple ligands for several different integrins (see Table II). Although RGD peptides inhibit ligand binding to integrins with an RGD recognition specificity (Table II), these receptors can discriminate among RGD-containing ligands. The context of the RGD sequence (flanking residues, three-dimensional presentation, and individual features of the integrin binding pockets) determine whether productive interactions occur (6). As an illustrative example of the nuances of the RGD recognition specificity, whereas both of the beta 3 integrins, alpha IIbbeta 3 and alpha Vbeta 3, recognize fibrinogen, which contains multiple RGD sequences, and RGD peptides inhibit the binding of fibrinogen to these integrins, both integrins can recognize other sequences in fibrinogen (7, 8). Thus, recognition of this seemingly simple tripeptide sequence is complex. A second set of fibronectin sequences also has received considerable attention: those recognized by alpha 4beta 1. Originally, the CS-1 sequence, which resides in an alternatively spliced segment of fibronectin, was determined to be a recognition site, but now several additional fibronectin sequences have been identified that interact with alpha 4beta 1 (9-11). Multiple recognition sites also exist in fibrinogen for alpha Mbeta 2 (12). Two generalizations can be derived from these examples: 1) integrin recognition specificities can often be reduced to small peptide sequences; and 2) peptide inhibition studies need to be complemented with other approaches to assess the role of specific sequences in ligand recognition by integrins.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Integrin recognition sequences


    Divalent Cations and Ligand Binding to Integrins
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

Integrins as Metalloproteins-- Each integrin heterodimer contains 3-5 divalent cation binding sites of relatively low affinity (µM-1 to mM-1), and the bound cations exert profound effects on integrin function. Collectively, these bound divalent ions can act as effectors, promoting ligand binding; as antagonists, inhibiting ligand binding; and as selectors, changing the ligand binding specificity. One proposal to explain the influential role of cations on integrin function is that ligand and divalent cation share a common binding pocket on the integrin. This hypothesis was supported by data showing that RGD ligands could displace two receptor-bound metal ions and that divalent ion and RGD peptide could bind, in a mutually exclusive manner, a peptide from the beta 3 subunit (13). Thus, a "displacement model" was proposed, in which RGD ligands initially form a ternary complex with receptor-bound divalent ion; then, as contacts between RGD and integrin stabilize, the divalent ion may be displaced. Recently, this model was extended to other integrins (14); collagen displaced Tb3+ bound to the I domain of the alpha 2 subunit. Dissection of the ligand binding reaction into ligand association and dissociation steps provided further insights into the roles of divalent ions in integrin function (15). Using surface plasmon resonance, the beta 3 integrins were shown to contain two classes of ion binding sites. One class must be occupied for ligand to bind, ligand-competent (LC)1 sites; and the second class has an inhibitory effect on ligand binding, I sites. The I site(s) display specificity for Ca2+ and increase the rate of ligand dissociation. Because the I sites are allosteric to the ligand binding pocket, they can bind Ca2+ even when ligand is prebound to integrin, providing a potential mechanism for the release of pre-existing cell-matrix contacts. Thus, it is the coordination between the LC and I cation binding sites that regulates the ligand binding event.

The Structural Basis of Divalent Ion Regulation-- There are at least two structurally distinct classes of ion binding motifs within integrins. A series of EF-hand-like domains are present in each of the integrin alpha  subunits (16). The integrin EF-hand loops lack a glutamate that is found at the 12th position in virtually all other EF-hand loops and is one of the ligands for Ca2+. The absence of this residue in integrins is likely to explain their lower affinity and selectivity for divalent ions. Two studies have examined the ion and ligand binding function of recombinant fragments containing the integrin EF-hands. Gulino et al. (17) produced a fragment composed of the four EF-hand sites within the alpha IIb subunit and found that it contained two affinity classes for Ca2+, which could also bind Mg2+ and Mn2+ and fibrinogen, a physiologic ligand for this integrin. These observations are generally consistent with results obtained from Ca2+ binding studies on the purified integrin (18) and synthetic peptides corresponding to the individual loops of each EF-hand (19). The EF-hand domains of the alpha 5 integrin also contain two affinity classes of ion binding sites and can bind fibronectin and RGD peptides (20). All four EF-hands were required for ligand binding, even though each pair of EF-hands was able to bind divalent ion.

The second type of cation binding site in integrins is a metal ion-dependent adhesion site (MIDAS) motif. The first evidence for a unique cation binding motif came from mutagenesis studies of the I domain of the alpha M subunit (21). Soon thereafter, the I domain of the alpha M subunit and other integrin alpha  subunits were crystallized (22-24). In Fig. 1, the crystal structures of two I domains are displayed with the MIDAS motif at their upper surface. Within the MIDAS motif, five separate residues coordinate the divalent ion. The first three are closely spaced within a DXSXS motif; the fourth is a threonine separated from the DXSXS in the primary structure by ~70 residues; and the fifth coordinating ligand is an aspartate about 100 residues downstream of the DXSXS. In the crystal structure, two of the alpha MI domains were linked via a Mg2+ ion in the MIDAS motif, and a glutamate from one I domain donated a sixth coordinating ligand to the Mg2+ bound in an adjacent I domain. This quirk in the crystal structure provided evidence that metal ion bound to the MIDAS can ligand with carboxylates donated from another protein, consistent with the cation displacement model. Indeed, this finding has prompted the hypothesis that such a structure is a snapshot of I domain bound with "ligand" and led to the prevailing notion that integrins bind to their ligands by "grabbing an Asp" (25).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Structures of representative I domains in integrin alpha  subunits. The ribbon diagrams are derived from the crystal structures of the I domains of the alpha M subunit (left) and the alpha L subunit (right). These I domains display the typical alpha  helical/beta strand fold of I domains. The cation bound in the MIDAS motif appears on the upper face of the structures. These crystal structures for the alpha M I domains were reported by Lee et al. (22) and by Qu and Leahy (23) for the alpha L.

All integrin beta  subunits may contain an ion binding site homologous to a MIDAS motif. This proposition stems from early work showing that a naturally occurring mutation of Y119D in integrin alpha IIbbeta 3 led to a receptor with abnormal ligand and cation binding functions (26), and it was proposed that this residue was part of an EF-hand. In retrospect, this ion binding site is more likely to be a MIDAS motif with Asp-119 being the first residue of the DXSXS motif. Mutation of any of these putative ion-coordinating residues within the beta 1, beta 2, beta 3, or beta 5 subunits ablates ligand binding to integrins (e.g. Refs. 27 and 28). Although the DXSXS motif appears to ligand with metal, the residues that constitute the fourth and fifth coordinating ligands in the beta  subunit MIDAS remain unclear and controversial (27-29). The three-dimensional structure of a beta  subunit may be necessary for resolution. Also, there is no structural information to locate the I Ca2+ binding site that is found on most integrins. All of the ion binding sites that have been located, the EF-hand sites in the alpha  subunits and the MIDAS motifs in the beta  subunits, appear to promote ion binding, i.e. are LC sites (15, 27, 30). One of the more tantalizing hypotheses regarding the location of this I site is that the ion binding site within the integrin beta  subunits can fold into either an EF-hand or a MIDAS domain. It may act as a MIDAS when Mn2+ or Mg2+ is present, but Ca2+ could induce an EF-hand conformation.

What Physiologic Role Do Ion Binding Sites Play in Regulating Integrins?-- Despite the strong influence of divalent ions on cell adhesion and ligand binding to integrins, information on the actual physiologic role of the ion binding sites is limited. One area where there is clear physiologic relevance is the adhesion of bone-resorbing osteoclasts. The osteoclast adheres to the bone surface primarily through alpha vbeta 3 (31). Adhesion to the bone surface must be tightly regulated to prevent excessive resorption. Interestingly, as mineralized bone is resorbed, the concentration of free Ca2+ beneath the osteoclast becomes elevated and induces osteoclast detachment and cessation of resorption. This effect may be mediated by the allosteric I Ca2+ binding site on alpha vbeta 3. Another situation where the levels of Ca2+ and Mg2+ fluctuate is in the fluid of healing wounds (32). During the initial healing process, the levels of Mg2+ increase, and the ratio of Mg2+/Ca2+ elevates from the normal plasma ratio of 0.4:1 to approach 1:1. Because Mg2+ generally promotes cell adhesion and Ca2+ is generally inhibitory, this increase in ratio may be "promigratory," facilitating wound closure. Finally, the ion binding sites also may play a role in integrin activation. Mn2+ increases the apparent affinity/avidity of multiple integrins for their ligands. Mn2+ binds to MIDAS motifs, and two conformations of the MIDAS can be distinguished by the manner in which the bound metal is coordinated (33, 34). Thus, Mn2+ could induce structural rearrangements in the I domains, which result in activation. An equally attractive hypothesis suggests that activation is regulated by the binding of Ca2+ to the allosteric I site. Occupation of this site by Ca2+ would maintain the integrin in a resting state.

    The beta 2 Integrins, Representative I Domain-containing Integrins
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

The beta 2 subfamily consists of four different integrin receptors, alpha Mbeta 2 (CD11b/CD18, Mac-1, CR3, Mo-1), alpha Lbeta 2 (CD11a/CD18, LFA-1), alpha Xbeta 2 (CD11c/CD18), and alpha Dbeta 2 (CD11d/CD18). These leukocyte integrins are involved in virtually every aspect of leukocyte function, including the immune response, adhesion to and transmigration through the endothelium, phagocytosis of pathogens, and leukocyte activation. The importance of the beta 2 integrins is underscored by the susceptibility of patients lacking these integrins to severe infections (see Ref. 35, and references therein). However, excessive activation of alpha Lbeta 2 and alpha Mbeta 2 contributes to sustained inflammation, reperfusion injury, and tissue damage. Recently, it has become possible to gauge the function of individual beta 2 integrin receptors in mice rendered selectively deficient in alpha Mbeta 2 and alpha Lbeta 2. The leukocyte integrins are the subject of a separate review in this miniseries. The discussion herein focuses primarily on their I domains and their role in ligand binding.

The alpha  subunits of all beta 2 integrins contain an inserted region of ~200 amino acids, termed the I or A domain. Highly conserved I domains are found in several other integrin alpha  subunits and other proteins, such as certain coagulation and complement proteins. I domains mediate protein-protein interactions, and in integrins, they are integrally involved in the binding of protein ligands (14, 22, 36). I domains, including those in integrin alpha  subunits, fold independently, can be expressed as recombinant fragments, and can bind ligands. Even though I domains are highly homologous to each other, they are highly selective for particular sets of ligands. At the same time, a single I domain can recognize multiple and structurally unrelated ligands (see ligand repertoire of alpha Mbeta 2 in Table I). Thus, it is the individual amino acid differences within the highly conserved structural fold of the I domains that impart ligand specificity.

The crystal structures of several integrin and non-integrin I domains have now been solved (e.g. Refs. 22-24). Each consists of five parallel beta  sheets surrounded by 5-6 alpha  helices, which are interconnected by flexible loops (see Fig. 1). The I domains of the beta 2 integrins contain the previously discussed cation binding MIDAS motif. In the I domains of alpha Mbeta 2 and alpha Lbeta 2 shown, the binding interface for several ligands has been mapped to the upper face, in close proximity to the bound cation (34, 37). Mutations in other faces of the I domains or outside the I domains can exert allosteric effects, either activating or inhibitory, on ligand binding (34, 38, 39).

Although the I domains dominate the ligand binding functions of their integrins, other regions of the alpha  subunits do influence ligand recognition. As examples, in alpha Mbeta 2 a mAb (OKM1) recognizing an epitope outside the I domain but in the alpha M subunit inhibits ligand binding (40); and the EF-hand regions in alpha Lbeta 2 and alpha 2beta 1, integrins with I domains in their alpha  subunits, contribute to ligand recognition (41, 42). The alpha M subunit, and perhaps other alpha  subunits, contains a lectin-like domain, which is involved in engagement of non-protein ligands, and occupancy may modulate the function of the I domain (43). The role of the beta  subunit in ligand binding to the leukocyte integrins is complicated. Though the importance of the beta  subunit in ligand recognition has been demonstrated using blocking mAbs and site-directed mutagenesis (e.g. Ref. 44), its direct involvement in ligand contact has yet to be established. Mutations in the beta 2 subunit, which abolish ligand binding, may exert a dominant-negative effect on ligand binding (45).

    Ligand Binding to Integrins without I Domains: Paradigms from alpha IIbbeta 3
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

The central role that platelet adhesive reactions play in hemostasis has focused significant efforts on defining alpha IIbbeta 3 recognition sequences within its ligands and the ligand contact points within the receptor. Many of the insights gained from these studies extrapolate to the beta 1 integrins because several of the beta 1 and both beta 3 integrins share a RGD recognition specificity. A second recognition specificity of particular importance to the function of alpha IIbbeta 3 is the C terminus of the fibrinogen gamma  chain (46). Each sequence contains an aspartic acid that is critical for recognition, perhaps through an interaction with receptor-bound cation (26). The two recognition peptides inhibit the binding of each other to alpha IIbbeta 3 but may bind to separate but allosterically linked sites (30, 47).

Substantial data have accumulated regarding the location of potential ligand contact sites within alpha IIbbeta 3. Mapping the epitopes of inhibitory mAbs, enzymatic digestion of native alpha IIbbeta 3, and the expression of soluble, recombinant forms of alpha IIbbeta 3 have indicated that the minimal ligand binding fragment contains the N-terminal half of each subunit (48). The specificity of alpha IIbbeta 3 versus alpha vbeta 3 for ligands was mapped to the N-terminal 334 residues of alpha IIb (49). Cross-linking studies have demonstrated the existence of ligand contact points in the N-terminal portions of alpha IIb (50) and beta 3 (51, 52), and it is likely that binding of macromolecular ligands to alpha IIbbeta 3 involves multiple contacts in each subunit. Essential residues identified to date can be grouped into two major regions: 1) the highly conserved segment, residues 95-400 of the 762 amino acids in beta 3; and 2) the seven N-terminal repeats of alpha IIb.

Two distinct, discontinuous regions within beta 3 clearly contribute to the ligand binding function of the receptor. RGD peptides cross-link to a region of beta 3 defined by Asp-109 to Glu-171 (52). An overlapping region of beta 3 (Glu-65 to Glu-220) was identified by cross-linking of RGD peptides to alpha Vbeta 3 (53). As noted previously, a naturally occurring point mutation in this region, D119Y, results in complete loss of ligand binding function (26), as do mutations at residues in this vicinity (54). The second potential ligand interactive site in beta 3 is defined by residues Ser-211 to Gly-222. Peptides corresponding to this sequence and antibodies directed against these peptides inhibit fibrinogen binding (55) as do natural mutations at beta 3 Arg-214 (56, 57). The importance of these two discontinuous regions of beta 3 is likely because of their participation in the formation of a MIDAS motif (21, 22) although, as noted above, it remains uncertain as to whether this region of beta 3 adopts an I domain fold (27, 29). Whereas the two discontinuous segments of beta 3 are involved in cation binding, they also may provide direct contact sites for ligand. Peptides and recombinant fragments of beta 3 bind fibrinogen and gamma -chain and RGD peptides (47, 58).

Studies of the ligand contacts in alpha IIb have established a role for its seven N-terminal repeats. As noted above, a recombinant fragment of alpha IIb containing the four EF-hand-like sequences binds fibrinogen in a Ca2+- and RGD-dependent manner (17). This region of alpha IIb has been further implicated in ligand binding because ligand mimetic peptides cross-link within the second cation binding repeat (50). Peptides from this region inhibit fibrinogen binding to alpha IIbbeta 3 and directly bind fibrinogen in a Ca2+-dependent manner (59, 60). Together, these data suggest a functional importance of the alpha IIb cation binding domains in ligand interactions. Paradoxically, a minimized form of alpha IIb, Leu-1 to Gly-233, which does not contain any of the divalent cation repeats, associated with beta 3 and recognized ligand (61).

Several attempts have been made at developing a structural model of integrin alpha  subunits. A recent model proposes that the seven N-terminal repeats adopt the fold of a beta -propeller domain (62). These domains contain seven four-stranded beta -sheets, or "blades," arranged in a torus around a pseudosymmetry axis. Enzymes with known beta -propeller folds have their active sites at the top of the beta -propeller, typically where adjacent loops run in opposite directions. Consistent with this hypothesis, the alpha IIb residues, Gly-184 to Gly-193, located in one loop, and alpha IIb Asp-224, located in a second loop, both predicted to be at the top of the beta -propeller, have been implicated in ligand binding by site-directed mutagenesis (63, 64). The identification of residues critical for ligand binding to alpha 4beta 1 and alpha 5beta 1 further supports the beta -propeller model (65, 66). Nevertheless, this model appears to contradict the data implicating the direct involvement of the alpha IIb and alpha 5 cation binding motifs in ligand binding. The model places these motifs on the lower surface of the propeller, spatially distant from the putative ligand contact points on the upper surface of the propeller.

The data discussed above confirm that the ligand binding pocket consists of portions of both the alpha IIb and beta 3 subunits and is consistent with the concept that binding of macromolecular ligands involves multiple contact points in the receptor. An emerging model (Fig. 2) is that alpha IIbbeta 3 has at least two distinct ligand binding domains that are intimately linked and allosterically controlled. alpha IIbbeta 3 exhibits significant conformational changes during activation and ligand binding. Therefore, it will be important to understand how these changes influence the individual ligand binding domains as well as how these changes affect the manner in which the alpha IIb and beta 3 subunits fold against each other to establish a structural basis for ligand binding to alpha IIbbeta 3.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Top (upper) and side (lower) views of a model of the ligand binding sites on alpha IIbbeta 3. The numbers refer to the seven repeats in the alpha IIb subunit, and the Ca2+ shown is bound to the MIDAS motif in the beta 3 subunit. In the low affinity state, receptor conformation does not favor binding of macromolecular ligands (L). Activation alters the spatial relationship of the two subunits and the conformation of individual binding domains to allow high affinity ligand interaction with multiple contact sites.


    FOOTNOTES

* This minireview will be reprinted in the 2000 Minireview Compendium, which will be available in December, 2000. This is the first article of four in the "Integrins Minireview Series."

§ To whom correspondence should be addressed: Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Mail Code: NB50, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-8200; Fax: 216-445-8204; E-mail: plowe@ccf.org.

Published, JBC Papers in Press, May 4, 2000, DOI 10.1074/jbc.R000003200

    ABBREVIATIONS

The abbreviations used are: LC, ligand competent; MIDAS, metal ion-dependent adhesion site; mAb, monoclonal antibody; ICAM, intracellular adhesion molecule; VCAM, vascular cell adhesion molecule; MAdCAM, mucosal addressin cell adhesion molecule.

    REFERENCES
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The beta 2 Integrins,...
Ligand Binding to Integrins...
REFERENCES

1. Hynes, R. O. (1987) Cell 48, 549-550
2. Green, L. J., Mould, A. P., and Humphries, M. J. (1998) Int. J. Biochem. Cell Biol. 30, 179-184
3. Porter, J. C., and Hogg, N. (1998) Trends Cell Biol. 8, 390-396
4. De Melker, A. A., and Sonnenberg, A. (1999) Bioessays 21, 499-509
5. Ruoslahti, E. (1996) Annu. Rev. Cell Biol. 12, 697-715
6. Haas, T. A., and Plow, E. F. (1994) Curr. Opin. Cell Biol. 6, 656-662
7. Yokoyama, K., Zhang, X.-P., Medved, L., and Takada, Y. (1999) Biochemistry 38, 5872-5877
8. Farrell, D. H., Thiagarajan, P., Chung, D. W., and Davie, E. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10729-10732
9. Wayner, E. A., Garcia-Pardo, A., Humphries, M. J., McDonald, J. A., and Carter, W. G. (1989) J. Cell Biol. 109, 1321-1330
10. Mould, A. P., Komoriya, A., Yamada, K. M., and Humphries, M. J. (1991) J. Biol. Chem. 266, 3579-3585
11. Domínguez-Jiménez, C., Sánchez-Aparicio, P., Albar, J. P., and García-Pardo, A. (1996) Cell Adhes. Commun. 4, 251-267
12. Ugarova, T. P., Solovjov, D. A., Zhang, L., Loukinov, D. I., Yee, V. C., Medved, L. V., and Plow, E. F. (1998) J. Biol. Chem. 273, 22519-22527
13. D'Souza, S. E., Haas, T. A., Piotrowicz, R. S., Byers-Ward, V., McGrath, D. E., Soule, H. R., Cierniewski, C. S., Plow, E. F., and Smith, J. W. (1994) Cell 79, 659-667
14. Dickeson, S. K., Bhattacharyya-Pakrasei, M., Mathis, N. L., Schlesinger, P. H., and Santoro, S. A. (1998) Biochemistry 37, 11280-11288
15. Hu, D. D., Barbas, C. F., III, and Smith, J. W. (1996) J. Biol. Chem. 271, 21745-21751
16. Tuckwell, D. S., Brass, A., and Humphries, M. J. (1992) Biochem. J. 285, 325-331
17. Gulino, D., Boudignon, C., Zhang, L. Y., Concord, E., Rabiet, M. J., and Marguerie, G. (1992) J. Biol. Chem. 267, 1001-1007
18. Rivas, G. A., and Gonzalez-Rodriguez, J. (1991) Biochem. J. 276, 35-40
19. Cierniewski, C. S., Haas, T. A., Smith, J. W., and Plow, E. F. (1994) Biochemistry 33, 12238-12246
20. Baneres, J. L., Roquet, F., Green, M., LeCalvez, H., and Parello, J. (1998) J. Biol. Chem. 273, 24744-24753
21. Michishita, M., Videm, V., and Arnaout, M. A. (1993) Cell 72, 857-867
22. Lee, J.-O., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Cell 80, 631-638
23. Qu, A., and Leahy, D. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10277-10281
24. Emsley, J., King, S. L., Bergelson, J. M., and Liddington, R. C. (1997) J. Biol. Chem. 272, 28512-28517
25. Bergelson, J. M., and Hemler, M. E. (1995) Curr. Biol. 5, 615-617
26. Loftus, J. C., O'Toole, T. E., Plow, E. F., Glass, A., Frelinger, A. L., and Ginsberg, M. H. (1990) Science 249, 915-918
27. Lin, C. K. E., Ratnikov, B. I., Tsai, P. M., Gonzalez, E. R., McDonald, S., Pelletier, A. J., and Smith, J. W. (1997) J. Biol. Chem. 272, 14236-14243
28. Puzon-McLaughlin, W., and Takada, Y. (1996) J. Biol. Chem. 271, 20438-20443
29. Tozer, E. C., Liddington, R. C., Sutcliffe, M. J., Smeeton, A. H., and Loftus, J. C. (1996) J. Biol. Chem. 271, 21978-21984
30. Hu, D. D., White, C. A., Panzer-Knodle, S., Page, J. D., Nicholson, N., and Smith, J. W. (1999) J. Biol. Chem. 274, 4633-4639
31. Ross, F. P., Chappel, J., Alvarez, J. I., Sander, D., Butler, W. T., Farach-Carson, M. C., Mintz, K. A., Robey, P. G., Teitelbaum, S. L., and Cheresh, D. A. (1993) J. Biol. Chem. 268, 9901-9907
32. Grzesiak, J. J., and Pierschbacher, M. D. (1995) J. Clin. Invest. 95, 227-233
33. Lee, J.-O., Bankston, L. A., Arnaout, M. A., and Liddington, R. C. (1995) Structure 3, 1333-1340
34. Li, R., Rieu, P., Griffith, D. L., Scott, D., and Arnaout, M. A. (1998) J. Cell Biol. 143, 1523-1534
35. Harris, E. S., McIntyre, T. M., Prescott, S. M., and Zimmerman, G. A. (2000) J. Biol. Chem. 275, 23409-23412
36. Randi, A. M., and Hogg, N. (1994) J. Biol. Chem. 269, 12395-12398
37. Zhang, L., and Plow, E. F. (1997) J. Biol. Chem. 272, 17558-17564
38. Zhang, L., and Plow, E. F. (1996) J. Biol. Chem. 271, 29953-29957
39. Oxvig, C., Lu, C., and Springer, T. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2215-2220
40. Thornton, B. P., Vetvicka, V., Pitman, M., Goldman, R. C., and Ross, G. D. (1996) J. Immunol. 156, 1235-1246
41. Stanley, P., Bates, P. A., Harvey, J., Bennett, R. I., and Hogg, N. (1994) EMBO J. 13, 1790-1798
42. Dickeson, S. K., Walsh, J. J., and Santoro, S. A. (1997) J. Biol. Chem. 272, 7661-7668
43. Vetvicka, V., Thornton, B. P., and Ross, G. D. (1996) J. Clin. Invest. 98, 50-61
44. Bajt, M. L., Goodman, T., and McGuire, S. L. (1995) J. Biol. Chem. 270, 94-98
45. Forsyth, C. B., Plow, E. F., and Zhang, L. (1998) J. Immunol. 161, 6198-6205
46. Kloczewiak, M., Timmons, S., and Hawiger, J. (1982) Biochem. Biophys. Res. Commun. 107, 181-187
47. Cierniewski, C. S., Byzova, T., Papierak, M., Haas, T. A., Niewiarowska, J., Zhang, L., Cieslak, M., and Plow, E. F. (1999) J. Biol. Chem. 274, 16923-16932
48. Loftus, J. C., Smith, J. W., and Ginsberg, M. H. (1994) J. Biol. Chem. 269, 25235-25238
49. Loftus, J. C., Halloran, C. E., Ginsberg, M. H., Feigen, L. P., Zablocki, J. A., and Smith, J. W. (1996) J. Biol. Chem. 271, 2033-2039
50. D'Souza, S. E., Ginsberg, M. H., Burke, T. A., and Plow, E. F. (1990) J. Biol. Chem. 265, 3440-3446
51. Santoro, S. A., and Lawing, W. J., Jr. (1987) Cell 48, 867-873
52. D'Souza, S. E., Ginsberg, M. H., Lam, S. C. T., and Plow, E. F. (1988) J. Biol. Chem. 263, 3943-3951
53. Smith, J. W., and Cheresh, D. A. (1988) J. Biol. Chem. 263, 18726-18731
54. Basani, R. B., Brown, D. L., Vilaire, G., Bennett, J. S., and Poncz, M. (1997) Blood 90, 3082-3088
55. Charo, I. F., Nannizzi, L., Phillips, D. R., Hsu, M. A., and Scarborough, R. M. (1991) J. Biol. Chem. 266, 1415-1421
56. Bajt, M. L., Ginsberg, M. H., Frelinger, A. L., III, Berndt, M. C., and Loftus, J. C. (1992) J. Biol. Chem. 267, 3789-3794
57. Lanza, F., Stierlé, A., Fournier, D., Morales, M., André, G., Nurden, A. T., and Cazenave, J.-P. (1992) J. Clin. Invest. 89, 1995-2004
58. Alemany, M., Concord, E., Garin, J., Vinçon, M., Giles, A., Marguerie, G., and Gulino, D. (1996) Blood 87, 592-601
59. D'Souza, S. E., Ginsberg, M. H., Matsueda, G. R., and Plow, E. F. (1991) Nature 350, 66-68
60. Taylor, D. B., and Gartner, T. K. (1992) J. Biol. Chem. 267, 11729-11733
61. McKay, B. S., Annis, D. S., Honda, S., Christie, D., and Kunicki, T. J. (1996) J. Biol. Chem. 271, 30544-30547
62. Springer, T. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 65-72
63. Kamata, T., Irie, A., Tokuhira, M., and Takada, Y. (1996) J. Biol. Chem. 271, 18610-18615
64. Tozer, E. C., Baker, E. K., Ginsberg, M. H., and Loftus, J. C. (1999) Blood 93, 918-924
65. Kamata, T., Puzon, W., and Takada, Y. (1995) Biochem. J. 305, 945-951
66. Mould, A. P., Burrows, L., and Humphries, M. J. (1998) J. Biol. Chem. 273, 25664-25667


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
M. V. Veettil, S. Sadagopan, N. Sharma-Walia, F.-Z. Wang, H. Raghu, L. Varga, and B. Chandran
Kaposi's Sarcoma-Associated Herpesvirus Forms a Multimolecular Complex of Integrins ({alpha}V{beta}5, {alpha}V{beta}3, and {alpha}3{beta}1) and CD98-xCT during Infection of Human Dermal Microvascular Endothelial Cells, and CD98-xCT Is Essential for the Postentry Stage of Infection
J. Virol., December 15, 2008; 82(24): 12126 - 12144.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. Weinlander, E. Naschberger, M. H. Lehmann, P. Tripal, W. Paster, H. Stockinger, C. Hohenadl, and M. Sturzl
Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin {alpha}4 expression
FASEB J, December 1, 2008; 22(12): 4168 - 4178.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. A. Chudakova, Y. H. Zeidan, B. W. Wheeler, J. Yu, S. A. Novgorodov, M. S. Kindy, Y. A. Hannun, and T. I. Gudz
Integrin-associated Lyn Kinase Promotes Cell Survival by Suppressing Acid Sphingomyelinase Activity
J. Biol. Chem., October 24, 2008; 283(43): 28806 - 28816.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
Y.-Q. Ma, J. Qin, C. Wu, and E. F. Plow
Kindlin-2 (Mig-2): a co-activator of {beta}3 integrins
J. Cell Biol., October 14, 2008; 181(3): 439 - 446.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-L. Tang, A. Vararattanavech, and S.-M. Tan
Urokinase-type Plasminogen Activator Receptor Induces Conformational Changes in the Integrin {alpha}M{beta}2 Headpiece and Reorientation of Its Transmembrane Domains
J. Biol. Chem., September 12, 2008; 283(37): 25392 - 25403.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Gaudreault, F. Vigneault, M.-E. Gingras, S. Leclerc, P. Carrier, L. Germain, and S. L. Guerin
Transcriptional Regulation of the Human {alpha}6 Integrin Gene by the Transcription Factor NFI during Corneal Wound Healing
Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3758 - 3767.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
W. Miltyk, A. Surazynski, J. Grabowska, and J. A. Palka
Prolidase Dependent Inhibition of Collagen Biosynthesis in Chinese Hamster Ovary Cells
J. Biochem., September 1, 2008; 144(3): 409 - 414.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. R. Schroeter, M. Leifheit, P. Sudholt, N.-M. Heida, C. Dellas, I. Rohm, F. Alves, M. Zientkowska, S. Rafail, M. Puls, et al.
Leptin Enhances the Recruitment of Endothelial Progenitor Cells Into Neointimal Lesions After Vascular Injury by Promoting Integrin-Mediated Adhesion
Circ. Res., August 29, 2008; 103(5): 536 - 544.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
D. B. Petropolis, J. C. Fernandes Rodrigues, B. da Rocha-Azevedo, and F. C. e Silva-Filho
The binding of Tritrichomonas foetus to immobilized laminin-1 and its role in the cytotoxicity exerted by the parasite
Microbiology, August 1, 2008; 154(8): 2283 - 2290.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Zhang, X.-T. Bai, K.-Y. Zhu, Y. Jin, M. Deng, H.-Y. Le, Y.-F. Fu, Y. Chen, J. Zhu, A. T. Look, et al.
In Vivo Interstitial Migration of Primitive Macrophages Mediated by JNK-Matrix Metalloproteinase 13 Signaling in Response to Acute Injury
J. Immunol., August 1, 2008; 181(3): 2155 - 2164.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
F. Shi and J. Sottile
Caveolin-1-dependent {beta}1 integrin endocytosis is a critical regulator of fibronectin turnover
J. Cell Sci., July 15, 2008; 121(14): 2360 - 2371.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Spitaleri, S. Mari, F. Curnis, C. Traversari, R. Longhi, C. Bordignon, A. Corti, G.-P. Rizzardi, and G. Musco
Structural Basis for the Interaction of isoDGR with the RGD-binding Site of {alpha}v{beta}3 Integrin
J. Biol. Chem., July 11, 2008; 283(28): 19757 - 19768.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. Chavakis, G. Carmona, C. Urbich, S. Gottig, R. Henschler, J. M. Penninger, A. M. Zeiher, T. Chavakis, and S. Dimmeler
Phosphatidylinositol-3-Kinase-{gamma} Is Integral to Homing Functions of Progenitor Cells
Circ. Res., April 25, 2008; 102(8): 942 - 949.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
W.-H. Tsai, C.-W. Chang, Y.-S. Lin, W.-J. Chuang, J.-J. Wu, C.-C. Liu, P.-J. Tsai, and M. T. Lin
Streptococcal Pyrogenic Exotoxin B-Induced Apoptosis in A549 Cells Is Mediated through {alpha}v{beta}3 Integrin and Fas
Infect. Immun., April 1, 2008; 76(4): 1349 - 1357.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Carmona, E. Chavakis, U. Koehl, A. M. Zeiher, and S. Dimmeler
Activation of Epac stimulates integrin-dependent homing of progenitor cells
Blood, March 1, 2008; 111(5): 2640 - 2646.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Q.-Q. Wang, H. Li, T. Oliver, M. Glogauer, J. Guo, and Y.-W. He
Integrin {beta}1 Regulates Phagosome Maturation in Macrophages through Rac Expression
J. Immunol., February 15, 2008; 180(4): 2419 - 2428.
[Abstract] [Full Text] [PDF]